Genetic Technologies (ASX:GTG) EPS without NRI: A$0.00 (TTM As of Jun. 2024)


What is Genetic Technologies EPS without NRI?

Genetic Technologies ASX:GTG EPS without NRI is A$0.00 as of Jun. 2024.

Genetic Technologies's earnings per share without non-recurring items for the three months ended in Jun. 2024 was A$0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was A$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Genetic Technologies's EPS without NRI or its related term are showing as below:

ASX:GTG's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 10.8
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Genetic Technologies's EPS (Diluted) for the three months ended in Jun. 2024 was A$0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$0.00.

Genetic Technologies's EPS (Basic) for the three months ended in Jun. 2024 was A$0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was A$0.00.


Genetic Technologies  (ASX:GTG) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Genetic Technologies EPS without NRI Related Terms


Genetic Technologies EPS without NRI Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies EPS without NRI Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.14 -0.08 0.00 0.02 0.01

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:GTG vs LDDD, NOTV, ATLN: EPS without NRI Comparison

For the Diagnostics & Research subindustry, Genetic Technologies's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Technologies PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's PE Ratio without NRI falls into.



Genetic Technologies EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of A$0.00 mean?
Genetic Technologies (ASX:GTG) has a EPS without NRI of A$0.00 as of Jun. 2024. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' EPS without NRI too high?
Genetic Technologies' current EPS without NRI is A$0.00.
How does Genetic Technologies' EPS without NRI compare to LDDD and NOTV?
Genetic Technologies' EPS without NRI of A$0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EPS without NRI is 10.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.80, based on 161 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Genetic Technologies and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Technologies's current EPS without NRI is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current EPS without NRI of A$0.00. The current EPS without NRI is A$0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current EPS without NRI is A$0.00 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.